Pancreatic Cancer Research: KRAS, Claudin 18.2 & Emerging Targets

Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rates of any cancer, with KRAS mutations present in over 90% of cases. The dense desmoplastic stroma and immunosuppressive TME make PDAC particularly resistant to immunotherapy, driving research into novel targets and combination strategies. For a broader view of all oncology reagent categories, see our Cancer Research Reagents hub.

Key Targets and Biomarkers

KRAS G12D is the most common KRAS mutation in PDAC (~40%), followed by G12V (~30%) and G12R (~15%). Anti-KRAS mutation-specific antibodies and recombinant mutant KRAS proteins are used in expression studies, drug screening, and neoantigen research.

Claudin 18.2 (CLDN18.2) is a tight junction protein overexpressed in gastric and pancreatic cancers. Zolbetuximab (anti-Claudin 18.2) achieved Phase III success in gastric cancer and is being evaluated in PDAC. Anti-CLDN18.2 antibodies, proteins, and research biosimilars support target expression profiling and drug development. Claudin 18.2 is also emerging as an ADC and CAR-T target.

Mesothelin (MSLN) is overexpressed in PDAC, mesothelioma, and ovarian cancer. Anti-mesothelin antibodies are used in IHC for expression scoring and as targeting moieties for ADCs, CAR-T cells, and immunotoxins. For diagnostic panel guidance, see our IHC Panel Design guide.

CA19-9 (sialyl Lewis A) is the standard serum biomarker for PDAC. Anti-CA19-9 antibodies and ELISA kits are used for monitoring treatment response and recurrence. Anti-VEGF and EGFR-targeted therapies have also been explored in PDAC combination regimens.

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi: 10.1038/s41591-018-0014-x

3. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi: 10.1038/s41571-021-00470-8

All products are for research use only. For technical support, contact order@abinscience.com.